40
Participants
Start Date
September 14, 2020
Primary Completion Date
February 3, 2022
Study Completion Date
February 3, 2022
Patritumab Deruxtecan
U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
UZ Antwerpen, Edegem
UZ Leuven, Leuven
Memorial Sloan Kettering Cancer Center, New York
Asst Grande Ospedale Metropolitano Niguarda, Milan
Centre Georges-Franois Leclerc, Dijon
John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Virgina Cancer Specialists, Fairfax
Duke University Medical Center, Durham
Hospital Universitario La Paz, Madrid
Hospital Universitario HM Sanchinarro, CIOCC, Madrid
Emory University, Atlanta
Moffitt Cancer Center, Tampa
Sarah Cannon, Nashville
West Cancer Center, Germantown
Hospital Universitario Virgen del Rocio, Seville
CHU Nantes, Nantes
Henry Ford Health System, Detroit
Mayo Clinic, Rochester
Northwestern Medical Faculty Foundation NMFF Hematology Oncology, Chicago
Washington University, St Louis
Nebraska Cancer Specialists, Omaha
Highlands Oncology, Fayetteville
Hospital St Antoine, Paris
Mary Crowley Cancer Research, Dallas
University of Texas Southwestern Medical Center, Dallas
MD Anderson Cancer Center University of Texas, Houston
University of Colorado Hospital, Aurora
Utah Cancer Specialists, Salt Lake City
City of Hope Comprehensive Cancer Center, Duarte
Rutgers Cancer Institute of New Jersey, New Brunswick
Aichi Cancer Center Hospital, Nagoya
National Hospital Organization - Osaka National Hospital (ONH), Osaka
Kindai University Hospital, Osaka
National Cancer Center Hospital East, Chiba
The Cancer Institute Hospital Of JFCR, Tokyo
Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Ostrów Wielkopolski
Szpital Kliniczny Przemienienia Pańskiego.University Hospital, Chemotherapy Department, Poznan
M Sklodowska Curie Memorial Cancer Center, Warsaw
Royal Marsden Hospital NHS, London
Sarah Cannon, London
M Sklodowska Curie Memorial Cancer Center, Warsaw
Hospital del Mar - Institut Hospital del Mar d'Investigacions Mediques IMIM, Barcelona
VHIO Valle de Hebron Instituto de Oncologia, Barcelona
Consorci Corporació Sanitària Parc Taulí de Sabadell, Sabadell
Royal Marsden Hospital NHS, London
Sarah Cannon Research Institute UK, London
Lead Sponsor
Daiichi Sankyo
INDUSTRY